Associations - PD-L2 overexpression

PD-L2 overexpression PD-L2 overexpression	Prostate Cancer Prostate Cancer	PD-L2 overexpression PD-L2 overexpression	Prostate Cancer Prostate Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	ipilimumab Sensitive: C3 – Early Trials	ipilimumab Sensitive: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L2 overexpression PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L2 overexpression PD-L2 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L2 overexpression PD-L2 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	capecitabine Sensitive: C3 – Early Trials	capecitabine Sensitive: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Acute Myelogenous Leukemia AML	PD-L2 overexpression PD-L2 overexpression	Acute Myelogenous Leukemia AML	avelumab Resistant: D – Preclinical	avelumab Resistant: D – Preclinical
PD-L2 overexpression PD-L2 overexpression	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	PD-L2 overexpression PD-L2 overexpression	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical
PD-L2 overexpression PD-L2 overexpression	Endometrial Cancer Endometrial Cancer	PD-L2 overexpression PD-L2 overexpression	Endometrial Cancer Endometrial Cancer	paclitaxel Sensitive: D – Preclinical	paclitaxel Sensitive: D – Preclinical